SunRock Biopharma and Escugen forge alliance to develop first-in-class CCR9-targeted ADC

CAR-T Digest - August 2020

16 June 2025: SunRock Biopharma and Escugen forge alliance to develop first-in-class CCR9-targeted ADC

SunRock Biopharma and Escugen have partnered to co-develop SRB123, a first-in-class ADC targeting CCR9, an antigen overexpressed in solid tumors like pancreatic, ovarian, and lung cancers
SRB123 combines SunRock’s high-affinity SRB1 antibody with Escugen’s next-gen EZWi-Fit linker-payload platform to enable targeted payload delivery and efficient tumor cell internalization
Preclinical data show strong anti-tumor activity, especially in CCR9+ tumors, positioning SRB123 as a promising therapeutic for aggressive, treatment-resistant cancers
The companies will jointly handle development, patent filings, and licensing, with the goal of generating preclinical proof-of-concept data to support rapid clinical advancement